Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

Eli Lilly has proposed investing $5.9 billion to build a pharmaceutical facility in Houston's Generation Park.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

A major pharmaceutical manufacturing company is considering planting ground in Houston, with a $5.7 billion proposed investment into a new facility. Eli Lilly applied for a tax abatement under ...

Drug prices in the United States are astronomical and climbing. Many analysts blame mergers and acquisitions among ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...